A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Fay, Michael P
Janes, Holly E
Baden, Lindsey R
El Sahly, Hana M
Fleming, Thomas R
Mehrotra, Devan V
Carpp, Lindsay N
Kublin, James G
Cohen, Myron S
Gilbert, Peter B
Neuzil, Kathleen M
JournalAnnals of Internal Medicine
PublisherAmerican College of Physicians
MetadataShow full item record
AbstractMultiple candidate vaccines to prevent COVID-19 have entered large-scale phase 3 placebo-controlled randomized clinical trials, and several have demonstrated substantial short-term efficacy. At some point after demonstration of substantial efficacy, placebo recipients should be offered the efficacious vaccine from their trial, which will occur before longer-term efficacy and safety are known. The absence of a placebo group could compromise assessment of longer-term vaccine effects. However, by continuing follow-up after vaccination of the placebo group, this study shows that placebo-controlled vaccine efficacy can be mathematically derived by assuming that the benefit of vaccination over time has the same profile for the original vaccine recipients and the original placebo recipients after their vaccination. Although this derivation provides less precise estimates than would be obtained by a standard trial where the placebo group remains unvaccinated, this proposed approach allows estimation of longer-term effect, including durability of vaccine efficacy and whether the vaccine eventually becomes harmful for some. Deferred vaccination, if done open-label, may lead to riskier behavior in the unblinded original vaccine group, confounding estimates of long-term vaccine efficacy. Hence, deferred vaccination via blinded crossover, where the vaccine group receives placebo and vice versa, would be the preferred way to assess vaccine durability and potential delayed harm. Deferred vaccination allows placebo recipients timely access to the vaccine when it would no longer be proper to maintain them on placebo, yet still allows important insights about immunologic and clinical effectiveness over time.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15459
- Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials.
- Authors: Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, Sahly HE, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM
- Issue date: 2020 Dec 14
- COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
- Authors: Fleming TR, Krause PR, Nason M, Longini IM, Henao-Restrepo AM
- Issue date: 2021 Jun
- COVID-19 vaccine trials: The potential for "hybrid" analyses.
- Authors: Fleming TR, Nason M, Krause PR, Longini IM, Henao-Restrepo AM
- Issue date: 2021 Aug
- Assessing vaccine durability in randomized trials following placebo crossover.
- Authors: Fintzi J, Follmann D
- Issue date: 2021 Nov 30
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
- Authors: Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F
- Issue date: 2021 Feb